Tag: tumor – ovary (malignant)

‘I Did Nothing Wrong:’ MDs Used Own Sperm for Fertility Patients

Martin D. Greenberg, MD, was sued in May for secretly using his own sperm to inseminate one of his infertility patients 38 years earlier. The...

How Patients Decide on Surgery

Patients consider the risk of cancer and menopause, as well as other factors, when making decisions about ovarian cancer prevention surgery, according to a small...

New Legal Push Aims to Speed Magic Mushrooms to Dying Patients

Erinn Baldeschwiler, mother of Shea McGinnis (left) and Gibson McGinnis, has been diagnosed with stage 4 metastatic breast cancer. Immunotherapy has helped with the physical...

Women Treated for Gynecologic Cancers Skip Doses of Oral Drugs

Oral agents are taking on an ever-greater role in the management of gynecologic cancers. However, women being treated for these cancers have less than ideal...

New Technologies Aim to Improve Ovarian Cancer Detection

Encouraging trends abound in the management of ovarian cancer. As rates of ovarian disease continue to decline, there has also been a notable increase in...

A Guide to the New Agents Reshaping Ovarian Cancer Treatment

The treatment of ovarian cancer has evolved considerably in the last few years, with the approval of several PARP inhibitors, antiangiogenic agents, and other therapies...

Two-Stage Surgery to Reduce Ovarian Cancer Risk Piques Interest

“Many physicians would assume that prevention of cancer, especially cancer as serious as ovarian cancer, trumps all other decision making, but when we really listen...

Hair Dye and Cancer Study ‘Offers Some Reassurance’

The largest study of its kind has found no positive association between personal use of permanent hair dye and the risk for most cancers and...

Gene Signature May Improve Prognostication in Ovarian Cancer

A new gene expression signature could improve on conventional risk factors when it comes to estimating prognosis and selecting treatment in patients with high-grade serous...

First PARP Inhibitor Approved for Metastatic Prostate Cancer

A completely new approach to the treatment of prostate cancer is now available to clinicians through the approval of the first PARP inhibitor for use...

Olaparib in Ovarian Cancer, Smoking and Lung Cancer

Here are the most important stories that Medscape Oncology’s editors picked for you to read today: A New Era for Ovarian Cancer Olaparib maintenance therapy...

One Strikeout, One Hit Against Low-Grade Serous Carcinomas

Two MEK inhibitors were tested against recurrent low-grade serous carcinomas of the ovaries, fallopian tubes, or peritoneum, but only one inhibitor offered clinical benefit over...

The Challenge of Continuing Clinical Trials

What your doctor is reading on Medscape.com: APRIL 22, 2020 — The impact of COVID-19 on national and international cancer research has been devastating....

Water-Only Fasting May Reduce Chemo Modifications

Patients with gynecologic malignancies who consumed only water for 24 hours before and 24 hours after each chemotherapy cycle had fewer dose delays and reductions...

Younger Gynecologic Cancer Patients at Risk for Early Bone Loss

Younger women treated for uterine or ovarian cancer are at increased risk for decreased bone mineral density and osteoporosis, especially in the first year after...

Financial Toxicity Is Common With Gynecologic Cancers

More than one-fifth of patients being treated for gynecologic malignancies experience financial toxicity, results of a single-center study suggest. Among 5,188 patients treated for gynecologic...

Survival & NAC Use Continue to Increase

Uptake of neoadjuvant chemotherapy (NAC) for the treatment of advanced ovarian cancer has increased dramatically since 2006 in the United States, but importantly, the median...